STAT Summit

Hear industry analysis from the top executives, researchers, policymakers, and patient advocates who have spoken at past STAT Summits. See our list of stories from past summits below.

All Coverage

Politics By Nicholas Florko

Moderate Democrats are still seeking changes to the party’s drug pricing package

STAT Summit By Megan Molteni

Extending the reach of gene therapies means hurdling not just scientific barriers but prices, too

STAT Summit By Elizabeth Cooney

‘Aduhelm left room’: Lilly CEO eyes competition with Biogen Alzheimer’s drug

What measuring blood sugar in real time means to patients

Health Tech By Elizabeth Cooney

Measuring blood sugar in real time is a game changer for patients — and a health tech success story

STAT Summit By STAT Staff

Watch: What patients and their families learned from facing a deadly disease

STAT Summit By STAT Staff

A conversation with cancer researcher Charles Sawyers, winner of the first STAT Biomedical Innovation Award

STAT Summit By STAT Staff

Watch: Top FDA official talks bringing the agency into a new age

STAT Summit By STAT Staff

Watch: CEO Daniel O’Day says Gilead is in a ‘sweet spot.’ What’s next?

In the Lab By STAT Staff

STAT Summit: The hypebusters who spoke truth to power

STAT Summit By STAT Staff

Watch: Top Biogen scientist explains why he’s confident in company’s drug for Alzheimer’s

Biotech By Nicholas Florko

This invite-only club is grooming new biotech CEOs — and helping make them less lonely, too

Politics By Nicholas Florko

Our drug policy often prioritizes eliminating rare disease. One researcher asks: Is that the right goal?

The Readout LOUD By Damian Garde, Rebecca Robbins and Adam Feuerstein

Listen: Warren’s awkward home front, the ethics of treating dwarfism, and the sound of STAT Summit

STAT Summit By STAT Staff

Watch: The state of biotech at time of innovation — and high prices

Pharmalot By Ed Silverman

Having gobbled up Celgene, the Bristol-Myers CEO ducks questions about his key rival

Biotech By Adam Feuerstein

Biogen’s top scientist nearly dares FDA not to approve Alzheimer’s drug

STAT Summit By Casey Ross

A bold prediction: Machine learning will yield new drug candidates within three years

Biotech By Kate Sheridan

‘The industry has earned it’: Three CEOs own up to biopharma’s bad reputation

In the Lab By Rebecca Robbins

Gene therapy pioneer says the field is behind — and that delivery technology is ‘embarrassing’

Health By Shraddha Chakradhar

Longtime cancer researcher Charles Sawyers named first STAT Biomedical Innovation Award winner

Biotech By Damian Garde

Most Read

Chelsea Clinton wants Trump, allies to build support for a Covid-19 vaccine

Bill Gates worries about a ‘dysfunctional’ approach to Covid-19 vaccine distribution

Fauci suggests he should have been ‘much more vocal’ about Covid-19 testing early in pandemic

STAT Summit: A conversation with Anthony Fauci, America’s virologist

Hopeful Covid-19 vaccine data won’t help hospitals that are overstretched now, experts say

Watch: VCs have to predict the future. Here’s what three of them expect next in biotech

Watch: Dr. James Wilson, a scientific pioneer, on the future of gene therapy

As FDA toils over how to regulate CBD, frustration builds on all sides

All Coverage

Moderate Democrats are still seeking changes to the party’s drug pricing package

Extending the reach of gene therapies means hurdling not just scientific barriers but prices, too

‘Aduhelm left room’: Lilly CEO eyes competition with Biogen Alzheimer’s drug

Measuring blood sugar in real time is a game changer for patients — and a health tech success story

Watch: What patients and their families learned from facing a deadly disease

A conversation with cancer researcher Charles Sawyers, winner of the first STAT Biomedical Innovation Award

Watch: Top FDA official talks bringing the agency into a new age

Watch: CEO Daniel O’Day says Gilead is in a ‘sweet spot.’ What’s next?

STAT Summit: The hypebusters who spoke truth to power

Watch: Top Biogen scientist explains why he’s confident in company’s drug for Alzheimer’s

This invite-only club is grooming new biotech CEOs — and helping make them less lonely, too

Our drug policy often prioritizes eliminating rare disease. One researcher asks: Is that the right goal?

Listen: Warren’s awkward home front, the ethics of treating dwarfism, and the sound of STAT Summit

Watch: The state of biotech at time of innovation — and high prices

Having gobbled up Celgene, the Bristol-Myers CEO ducks questions about his key rival

Biogen’s top scientist nearly dares FDA not to approve Alzheimer’s drug

A bold prediction: Machine learning will yield new drug candidates within three years

‘The industry has earned it’: Three CEOs own up to biopharma’s bad reputation

Gene therapy pioneer says the field is behind — and that delivery technology is ‘embarrassing’

Longtime cancer researcher Charles Sawyers named first STAT Biomedical Innovation Award winner

Gilead CEO Daniel O’Day says company is in an ‘acquisitive mode’

Subscribe to STAT for $15 per month lorem ipsum